Key facts
- It has raised $4.1M; the latest was Accelerator/Incubator in May 2024.
- Notable investors include Bpifrance, Capital Grand Est, Conectus, Enseignement Supérieur et de la Recherche, French Ministry of Education Nationale — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Syndivia
- ·The full record, as it builds
Funding rounds
No funding rounds for Syndivia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Syndivia
Developer of cancer therapeutics designed to make new therapies for patients with difficult-to-treat tumor indications. The company offers targeted ADCs with optimal drug-to-antibody ratios, enabling healthcare professionals to improve antitumor efficacy and safety for patients.
- Sector
- Healthcare
- HQ
- Strasbourg, France
- Founded
- 2014
- Employees
- 6
- Website
- syndivia.com/
- Ownership
- Privately Held (backing)
Syndivia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Syndivia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Syndivia in its N-PORT filings yet. We sweep new filings monthly.